With regard to treatment, IFN-β treatment has been shown to increase CD4+ T-cell surface expression of CCR4, while the expression of CCR4 was significantly lower in untreated MS patients compared with healthy volunteers [86]. Here, IFNB1 is linked to myeloid sarcoma.